PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30111817-3	2019	Here we report that NSCLC cells with acquired resistance to gefitinib or osimertinib (AZD9291) exhibit EMT features, with a decrease in E-cadherin, and increases in vimentin and stemness, without possessing any EGFR secondary mutations.	osimertinib	86-93	cadherin 1	Homo sapiens	136-146	
35287683-10	2022	In the LM xenograft model with H1975 cells, the combined treatment significantly increased the effective intracranial concentration of osimertinib, modulated the level of E-cadherin and downregulated the levels of EGFR and downstream signaling pathways including p-AKT and reduced tumor microvessel density (TMD), indicated that combined osimertinib with bevacizumab may exhibit a synergistic effect in EGFR-mutant LM model possibly by modulating the level of E-cadherin.	osimertinib	135-146	cadherin 1	Homo sapiens	460-470	
33992097-11	2021	ID1 expression levels was closely related to E-cadherin and vimentin in both osimertinib-sensitive and resistant cells.	osimertinib	77-88	cadherin 1	Homo sapiens	45-55